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Deﬁciencies in serotonergic neurotransmission are involved in the pathophysiology of depression. Due to
its modulatory effect on serotonin (5-HT) release, the 5-HT1A-receptor is thought to play a decisive role in
the therapy of this mood disorder. However, it is not fully understood how antidepressant effects are
mediated by pre- and postsynaptic receptor sites. In this study we examined the impact of postsynaptic
5-HT1A-receptor over-expression in corticolimbic areas of male and female mice on the performance in
the forced swim-test (FST). Furthermore, we investigated their response to the serotonin selective
reuptake inhibitor (SSRI) citalopram in comparison to the selective noradrenaline reuptake inhibitor
reboxetine, as well as the partial 5-HT1A-receptor agonists, buspirone and S 15535. Additionally, these
drugs were evaluated in the open ﬁeld-test in order to observe effects on motor activity. The density of
5-HT1A-receptors in discrete corticolimbic regions was determined in detail by quantitative autoradi-
ography with [3H]8eOHeDPAT to investigate genotype as well as sex dependent differences in the
expression pattern. [3H]8eOHeDPAT binding differed depending on sex with female mice of both
genotypes displaying higher receptor binding in distinct brain areas. In the FST untreated male but not
female over-expressing (OE) mice showed an antidepressant-like behaviour compared to wild-type (WT)
mice. Citalopram yielded an antidepressant effect without inﬂuencing locomotor activity in OE mice but
not in WT mice. Reboxetine had no antidepressant-like effect in OE mice, but sex-dependently in WT
mice. The two partial agonists, buspirone and S 15535 produced no antidepressant-like activity in both
genotypes and sexes, but aberrant motor effects. The antidepressant-like phenotype of male transgenic
mice accounts for an involvement of postsynaptic 5-HT1A-receptors in the FST behaviour. In addition, the
selective over-expression of postsynaptic 5-HT1A-receptors in mice contributes to the antidepressant
response to citalopram in the FST. Although further pharmacological analysis is required, the data
provide novel support for a role of postsynaptic 5-HT1A-receptors in the effects of SSRIs.
This article is part of a Special Issue entitled ‘Serotonin: The New Wave’.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The serotonin (5-HT) hypothesis of depression has been well
established since the late 1960s. Particularly, deﬁcits in seroto-
nergic neurotransmission were found to play a key role in the
pathophysiology of major depression, which has led to the devel-
opment of selective serotonin reuptake inhibitors (SSRIs) (see
review by Millan, 2006).x: þ49 30 838 53112.
(B. Bert).
Y-NC-ND license.Several subtypes of the 5-HT-receptor family, which contains at
least 14 members, have been associated with depressive disorders.
Within this family the 5-HT1A-receptor has gained increasing
interest in the auxiliary therapy of depression. The 5-HT1A-receptor
stands out because of its appearance on pre- and postsynaptic sites
and its modulatory effect on serotonergic neurotransmission.
Presynaptic 5-HT1A-autoreceptors are located in high densities
somatodendritically in the raphe nuclei where they control via
a negative feedback mechanism the ﬁring rate of serotonergic
neurons and therefore decrease 5-HT release into the synaptic cleft
(Ago et al., 2003; Albert et al., 1990; Blier and de Montigny, 1990).
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receptors on glutamatergic pyramidal cells and on GABAergic
interneurons in the hippocampus, cortical regions, septum, amyg-
dala, andhypothalamus (Chessell et al.,1993; Pompeiano et al.,1992;
Wedzonyet al., 2007)where their activation leads to decreasedﬁring
rates of the respective neurons (e.g. Blier and de Montigny, 1990;
Sprouse and Aghajanian, 1988; Tanaka and North, 1993).
The use of 5-HT1A-receptor agonists for the treatment of
depression has been widely discussed and is partially based on the
results of receptor binding studies in humans: In suicidal victims and
patients suffering from major depression an increased density of
presynaptic 5-HT1A-receptors was revealed (Boldrini et al., 2008;
Stockmeier et al., 1998) and could be a reason for the diminished
5-HT-levels found post-mortem in depressed patients. The role of
the 5-HT1A-receptor in the pathophysiology of depression has been
strengthened by the detection of the C(-1019)G 5-HT1A-promoter
polymorphism. This allele iswidely spread in depressed patients and
was linked to a higher 5-HT1A-receptor binding in the raphe nuclei
(Lemonde et al., 2003). These two observations in humans suggested
that drugs desensitising presynaptic 5-HT1A-receptor sites could be
beneﬁcial for the therapy of depression, but monotherapy with
partial 5-HT1A-receptor agonists, like buspirone and tandospirone,
showed only a weak antidepressant response (McGrath et al., 1994;
Robinson et al.,1990; Stahl et al.,1998). Partial agonists behave as full
agonists at somatodendritic receptors and do not exert full agonist
effects at postsynaptic 5-HT1A-receptors (Savitz et al., 2009), there-
fore they might not be sufﬁcient for the therapy of depression.
Preclinical data stand to reason that activation of postsynaptic
5-HT1A-receptors, especially in the forebrain, is important for the
antidepressant effect of 5-HT1A-receptor agonists (see Blier and
Ward, 2003 for review). The relevance of postsynaptic 5-HT1A-
receptors for depression is supported by the novel agonist F15599
with high selectivity and efﬁcacy at postsynaptic 5-HT1A-receptors.
F15599 revealed high antidepressant activity in respective animal
models and thus promises to be an improvement in the therapy of
depression (Assie et al., 2010; Llado-Pelfort et al., 2010).
In order to specify the role of the postsynaptic 5-HT1A-receptor
our group has developed a transgenic mouse line (OE mice) with
a stable over-expression of the 5-HT1A-receptor predominantly in
the outer cortical layers and CA3 region of the hippocampus (Bert
et al., 2006). In a previous publication we were able to show that
these transgenic mice respond with an exaggerated serotonin-
syndrome to 8eOHeDPAT even at low doses (Bert et al., 2006), an
effect that is clearly postsynaptically mediated. In addition,
8eOHeDPAT induced anterograde amnesia in the inhibitory
avoidance-test only in transgenic mice (Bert et al., 2009),
a response which has also been associated to 5-HT1A-hetero-
receptor activation (Carli et al., 1992; Misane et al., 1998). The lack
of anxiolytic activity of 8eOHeDPAT in the elevated plus maze-test
(Bert et al., 2006) underlines that in our transgenic mice the surplus
receptors are postsynaptically expressed. All previous ﬁndings
indicate that the over-expressed 5-HT1A-receptors are pharmaco-
logically active.
In the present study we examine the behaviour of OE and wild-
type (WT) mice in the forced swim-test (FST) and their response to
speciﬁc antidepressants with respect to genotype and sex speciﬁc
differences. Firstly, we speciﬁed and quantiﬁed the 5-HT1A-receptor
over-expression by receptor-autoradiography with [3H] labelled
8eOHeDPAT. Then we investigated the response of male and female
WT and OE mice to the SSRI citalopram, which is highly selective for
serotonin reuptake sites andhasno secondarypharmacological action,
and compared its effect to the effects of the selective noradrenaline
reuptake inhibitor (NARI) reboxetine. Furthermore, we examined the
effects of two partial 5-HT1A-receptor agonists, buspirone and S 15535
in the FST. Compared to buspirone, S 15535 exhibits a very lowintrinsic activity and has additionally a higher afﬁnity to postsynaptic
than to presynaptic 5-HT1A-receptors (Newman-Tancredi et al., 1998a,
1998b). In order to identify genotype-related drug effects on motor
activity (Cryan et al., 2005b) doses of substances that were effective in
the FST were evaluated in the open ﬁeld-test (OFT).
2. Methods
2.1. Animals
We used male and female transgenic mice (background: NMRI mice by Harlan-
Winkelmann, Borchen, Germany) with a stable over-expression of the 5-HT1A-
receptor as well as male and female NMRI wild-type mice at the age of 12e14 weeks
(the generation of mice was previously described in detail (Bert et al., 2006)). Mice
were separately bred and group-housed by sex and genotype with 4e7 animals per
cage (Makrolon type IV) under standard laboratory conditions (22  2 C room
temperature, 55  10% humidity) with an artiﬁcial 12 h lightedark cycle (lights on
06.00e18.00 h). Animals had free access to food (Altromin 1326, Lage, Germany) and
tap water. Experiments were performed in accordance with the guidelines of the
German Animal Welfare Act and were approved by the Berlin State Authority
(“Landesamt für Gesundheit und Soziales”, G 0107/06, G 0165/08, A 0432/08).
2.2. In vitro autoradiography
2.2.1. Tissue preparation
Immediately after decapitation, the brains were rapidly removed, frozen on
crushed dry ice and stored at 80 C until further use. Frontal brain slices (20 mm)
were cut with a microtome-cryostat (Leica, Bensheim, Germany), thaw-mounted
onto glass slides, air-dried for 120 min, and stored at 20 C. Slices for 5-HT1A-
receptor analysis were determined based on the mouse brain atlas of Franklin and
Paxinos (1997). Three different planes were used (see Fig. 1). Speciﬁc [3H]
8eOHeDPAT binding was analysed in the following brain regions: Plane 1
(bregma: þ1.54 mm): frontoparietal and piriform cortex, tenia tecta, lateral septum,
and claustrum/endopiriform nucleus; plane 2 (bregma: 2.18 mm): retrosplenial
and parietal cortex, the anterior hippocampus (CA1, CA2, CA3, and dentate gyrus),
amygdala (medial, basal/lateral, and cortical), and hypothalamus; plane 3
(bregma:4.36mm): dorsal raphe nucleus (DRN) andmedian raphe nucleus (MRN).
2.2.2. Incubation and data analysis
5-HT1A-receptor autoradiography was performed as described by Schiller et al.
(2003). The tritium [3H] labelled 5-HT1A-receptor agonist 8eOHeDPAT (Perkin
Elmer, Rodgau-Jügesheim, Germany) was used in a concentration of 2 nM.
Nonspeciﬁc bindingwas determined on adjacent slices in the presence of 10 mMMM
77 (1-(2-Methoxyphenyl)-4-[(4-succinimido)butyl]-piperazine, a 5-HT1A-receptor
antagonist; Biotrend, Cologne, Germany). The glass slides were pre-incubated in
50 mM TriseHCl (pH 7.4) containing 120 mM NaCl and 4 mM CaCl2 for 15 min at
room temperature (RT). The next step was the main incubation (50 mM TriseHCl,
60 min, RT) in order to assess total (only radioligand) and nonspeciﬁc
(radioligand þ displacer) binding. After incubation, all slides were washed twice for
10 min in ice-cold pre-incubation buffer and brieﬂy dipped into distilled water.
Finally, the slides were dried in a stream of cold air. In order to avoid procedural bias,
comparative brain slices of all groupswere incubated simultaneously. All slides were
exposed to [3H] sensitive imaging plates (Raytest, Straubenhardt, Germany) together
with [3H] microscale standards (Amersham Biosciences, Piscataway, USA) for 10
days. Afterwards, the imaging plates were scanned with a bioimaging analyser (Fuji,
Japan) and evaluated using the software AIDA 2.11 (Raytest, Straubenhardt,
Germany). The speciﬁc binding of [3H]8eOHeDPAT was calculated and displayed in
fmol/mg protein. Nissl-stained reference slices, adjacent to the sections which had
been processed for autoradiography, were used to identify brain regions. All bilat-
erally localised brain regions were analysed separately on the left and on the right
hemisphere (cortical and hippocampal regions as well as the claustrum/endopiri-
form nucleus and the different amygdaloid nuclei). No signiﬁcant difference in [3H]
8eOHeDPAT-speciﬁc binding was observed between left and right hemisphere in
the different brain regions that were analysed. Therefore, the values from the left
and right hemisphere of 6 mice per group were summarised as one mean (n ¼ 12).
All regions located at the midline of the brain were analysed as a whole region (i.e.,
tenia tecta, lateral septum, hypothalamus, DRN, and MRN). The mean [3H]
8eOHeDPAT binding for each of these brain regions was calculated based on
a maximum of 6 single values in each group (n ¼ 6). Data could not be evaluated in
some cases as the brain tissue was destroyed during incubation or the slice used for
incubation did not entirely match the brain plane necessary for quantitative
densitometry. Therefore, the means for each group were calculated from values of
4e6 animals (Table 1).
2.3. Behavioural experiments
All behavioural experiments were conducted in a sound-attenuated chamber
between (8.30 and 12.00 a.m.). The animals were moved into an anteroom at least
Fig. 1. Sample pictures of [3H]8eOHeDPAT binding in male and female wild-type (WT) and over-expressing mice (OE) and Nissl-stained mice brain slices of the anatomical planes
that were used. Plane 1: bregma: þ1.54 mm, plane 2: bregma: 2.18 mm, plane 3: bregma: 4.36 mm. 5-HT1A-receptor binding is illustrated by increasing intensity in yellow to red
colour. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
L. Günther et al. / Neuropharmacology 61 (2011) 433e441 4351 h before the start of the experiment. Between 6 and 13 animals were used per
group (group sizes are indicated in the ﬁgures). A new cohort of animals was used
for each experiment and treatment.
2.3.1. Forced swim-test (FST)
According to Porsolt et al. (1978) animals were lowered into a 5 l glass-beaker
(Ø 19 cm) ﬁlled with warm water (24 C) to a height of 15 cm. Their behaviour was
observed for 6 min. The time animals spent ﬂoating on the water surface without any
movement, except for minimal activity which kept them from drowning, was recorded.
This behaviour isdeﬁnedas “behavioural despair”and isdecreasedby theadministration
of antidepressants. The immobility time [s] was measured manually using a compu-
terised tracking system (TSE VideoMot, Version 1.43, Bad Homburg, Germany).
2.3.2. Open ﬁeld-test (OFT)
The OFT was conducted in order to evaluate differences in drug effects on motor
activity of both the genotypes that could interfere with the behaviour in the FST.
Therefore, doses that were effective in the FST were tested in the OFT. The open ﬁeld
(50 cm  50 cm  30 cm) consisted of white painted wood. The ﬂoor was covered
with a black mat to avoid aversiveness. A halogen lamp provided the same lightTable 1
[3H]8eOHeDPAT binding in fmol/mg protein in male and female wild-type (WT) and ov
nucleus; MRN ¼ median raphe nucleus; p < 0.0125 after Bonferroni correction.
Region of Interest Male
WT OE P
Cortex
Frontoparietal cortex 100.95  9.62 715.69  55.36 0.00
Piriform cortex 49.59  3.28 127.08  9.21 <0.00
Retrosplenial cortex 32.13  5.04 173.50  7.84 0.00
Parietal cortex 71.21  4.68 669.71  23.52 <0.00
Hippocampus
CA1 548.81  18.00 547.13  18.00 1.00
CA2 278.34  23.28 252.09  24.55 0.47
CA3 79.98  5.49 498.69  16.31 <0.00
Dentate gyrus 128.09  5.89 143.69  7.79 0.16
Amygdala
Medial amygdala 74.90  7.17 123.79  7.39 <0.00
Basal/lateral amygdala 24.24  2.59 94.06  5.51 <0.00
Cortical amygdala 81.88  8.86 160.81  8.50 <0.00
Hypothalamus 39.41  5.86 80.93  3.32 0.00
Lateral septum 111.02  10.42 210.24  24.49 0.00
Claustrum/endopiriform nucleus 182.11  10.60 313.36  21.42 0.00
Tenia tecta 100.45  8.77 302.35  45.11 0.00
Raphe nuclei
DRN 211.52  16.53 191.91  5.85 0.39
MRN 48.03  2.52 49.56  8.24 0.62intensity as in the animal facilities (approximately 250 lx in the centre). The animals
were initially placed in the centre of the open ﬁeld. Their ambulatory behaviour was
recorded for 10 min and total distance [m] was measured using a computer-based
system (VideoMot2, TSE Systems, Bad Homburg, Germany).
2.4. Drugs
Citalopram, buspirone (both Tocris, Avonmouth, UK), and reboxetine (generous
donation from Pﬁzer, Groton, USA) were freshly dissolved in physiological saline
solution. S 15535 (generous donation from Servier, Croissy/Seine, France) was
freshly dissolved in sterile distilled water. All drug solutions and vehicle (saline or
distilled water) were injected intraperitoneally (i.p.) with a volume of 10 ml/kg
30 min before testing.
2.5. Statistics
Values are presented as means and standard errors of the mean (SEM). Graphs
were created using SigmaPlot 11.0 software. Data was analysed with SigmaStat 3.0
software programme. All data were tested for normal distribution with theer-expressing (OE) mice. Data are presented as means  SEM. DRN ¼ dorsal raphe
Female Male vs. Female
WT OE P WT OE
4 121.11  11.72 831.23  50.53 0.010 0.190 0.310
1 41.48  3.83 149.00  10.28 <0.010 0.112 0.223
2 28.65  2.36 144.59  13.15 0.004 0.931 0.132
1 87.16  5.94 842.27  23.17 <0.001 0.093 <0.001
0 564.68  15.81 596.73  18.34 0.166 0.805 0.065
0 272.93  21.02 427.44  16.54 <0.001 0.972 <0.001
1 82.34  5.17 547.22  14.92 <0.001 0.751 0.049
8 152.12  7.42 143.47  6.16 0.448 0.027 0.854
1 85.68  5.46 122.36  8.94 0.004 0.379 0.896
1 35.50  2.23 108.44  5.18 <0.001 0.006 0.101
1 106.25  6.58 193.81  11.87 <0.001 0.061 0.049
2 53.15  3.31 99.55  4.28 0.004 0.082 0.009
9 157.65  16.91 241.47  14.41 0.010 0.032 0.394
4 231.89  4.96 337.61  15.97 0.002 0.002 0.653
4 149.26  14.26 320.81  16.62 0.010 0.111 0.485
3 228.66  14.00 239.86  20.89 0.724 0.497 0.262
9 80.10  3.68 76.68  4.08 0.579 0.005 0.048
Fig. 2. Immobility time of untreated male (M) and female (F) wild-type (WT) and over-
expressing mice (OE) in the FST. Data are presented as means þ SEM, *p < 0.05 vs. WT.
Fig. 3. Effects of citalopram on immobility in male and female wild-type (WT) and
transgenic mice (OE) in the FST. Data are presented as means þ SEM, *p < 0.05 vs.
vehicle (Veh).
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therefore analysed with non-parametric tests. ManneWhitney-U-tests or Krus-
kalleWallis ANOVAs were used for the behavioural data in order to compare two or
more groups, respectively. Dunn’s tests were conducted for post-hoc comparison
versus control, e.g. WT or vehicle, respectively. A probability value of p < 0.05 was
considered to be statistically signiﬁcant. Data from the 5-HT1A-receptor autoradi-
ography was analysed by using the ManneWhitney-U-tests; following Bonferroni
correction, p was deﬁned as <0.0125.
3. Results
3.1. Receptor-autoradiography with [3H]8eOHeDPAT
Representative sample slices of [3H]8eOHeDPAT binding of
male and female WT and OE mice are shown in Fig. 1.
3.1.1. OE vs. WT mice
Male OE mice display signiﬁcantly higher 5-HT1A-receptor
binding in all investigated cortical areas (from 2.5-fold for the
piriform cortex to 9-fold for the parietal cortex) in comparison to
male WT mice (see Table 1). In the CA3 region of the hippocampus
[3H]8eOHeDPAT binding was exceedingly higher (6-fold) in male
OEmice than inmalesWTmice. In the sub-regions of the amygdala,
hypothalamus, claustrum/endopiriform nucleus, and tenia tecta
5-HT1A-receptor binding was 1.5e3.5-fold increased in male OE
mice. We did not detect differences in [3H]8eOHeDPAT binding
between male OE and male WT mice in the DRN and MRN (see
Table 1).
In general, the level and distribution pattern of over-expressed
5-HT1A-receptors were similar in female and male OE mice, except
for the additional over-expression in the CA2 region of the hippo-
campus of female OE mice (see Table 1).
3.1.2. Male vs. female mice
Sex differences were detected in distinct brain regions of WT as
well as OE mice. Female WT mice showed signiﬁcantly higher
5-HT1A-receptor binding in the basolateral amygdala, claustrum,
and MRN than male WT mice. Female OE mice displayed higher
[3H]8eOHeDPAT binding in the CA2 region, parietal cortex, and
hypothalamus than male OE mice (see Table 1).
3.2. Behavioural experiments
3.2.1. Untreated animals
In the FST, male OE mice spent signiﬁcantly (p ¼ 0.030) more
time trying to escape the glass cylinder than male WT mice
pointing to an antidepressant-like behaviour (Fig. 2). In contrast,
female OE and WT mice showed comparable immobility times in
the FST (p ¼ 0.307, Fig. 2).
3.2.2. Citalopram
Doses of 5.0 and 10.0 mg/kg citalopram decreased immobility in
the FST in male WT mice (p ¼ 0.021; Fig. 3). However, this was
accompanied by an increase in motor activity in the OFT at both
doses (p< 0.001; Table 2). Inmale OEmice both doses of citalopram
reduced immobility in the FST (p < 0.001; Fig. 3) without affecting
motor activity in the OFT (p¼ 0.137; Table 2). It has to be noted that
the administration of 5.0 and 10.0 mg/kg citalopram induced in 4
out of 12 OEmice abnormal swimming behaviour, such as distorted
swimming postures. These animals were excluded from the
experiment. Both doses of citalopram had no inﬂuence on the
ambulatory behaviour of male OE mice in the OFT.
Citalopram did not affect the escaping behaviour of female WT
mice in the FST (p¼ 0.133; Fig. 3). In contrast, in female OE mice 5.0
and 10.0 mg/kg citalopram reduced immobility in the FST
(p ¼ 0.004; Fig. 3). Motor activity of female OE mice was notinﬂuenced by both doses of citalopram (p ¼ 0.805; Table 2). Similar
to male OE mice, distorted swimming postures were also observed
in transgenic females. Two out of 12 animals (5 mg/kg citalopram)
and 5 out of 11 animals (10 mg/kg citalopram) were excluded from
the experiments.
3.2.3. Reboxetine
Reboxetine had no effect on the swimming behaviour of either
male OE (p ¼ 0.558) or male WT mice (p ¼ 0.103; Fig. 4). In female
WT mice 20 mg/kg reboxetine reduced immobility in the FST
(p ¼ 0.029; Fig. 4). In the OFT, this dose caused hypoactivity in
female WT mice (p ¼ 0.004; Table 2). Swimming behaviour of
female OE mice remained unchanged by the treatment with
reboxetine (p ¼ 0.253; Fig. 4).
Table 2
Effects of citalopram, reboxetine, and buspirone (with the effective doses derived
from the FST) on total distance in the OFT in male and female wild-type (WT) and
over-expressing mice (OE) mice. Data are presented as means  SEM.
Dosis [mg/kg] Distance [m] [n]
Citalopram
WT male vehicle 37.72  2.11 13
5.0 64.80  2.58* 6
10.0 71.61  2.54* 7
OE male vehicle 45.21  1.78 12
5.0 48.28  1.21 6
10.0 53.93  4.04 5
OE female vehicle 40.35  5.11 5
5.0 50.54  1.65 6
10.0 51.98  1.34 6
Reboxetine
WT female vehicle 52.55  4.40 6
20.0 29.95  3.24* 6
Buspirone
WT male vehicle 34.40  2.13 8
3.0 23.72  2.16* 9
*p < 0.05 vs. vehicle by Dunn’s tests.
Fig. 5. Effects of buspirone on immobility in male and female wild-type (WT) and
transgenic mice (OE) in the FST. Data are presented as means þ SEM. Single values are
shown for OE mice treated with 3 mg/kg buspirone, *p < 0.05 vs. vehicle (Veh).
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At the highest dose (3.0 mg/kg), buspirone increased immobility
in male WT mice in the FST (p < 0.001; Fig. 5). However, the same
dose also decreased motor activity in the OFT (p ¼ 0.011; Table 2).
Buspirone had no effect on the escape behaviour of male OE mice
(p ¼ 0.901; Fig. 5) in the FST, but 3 mg/kg buspirone produced
a similar distorted swimming behaviour in 9 out of 12 animals as
described above for citalopram (the remaining animals are shown
as single values in Fig. 5).
In femaleWTmice, buspirone had no effect on the immobility in
the FST (p¼ 0.885; Fig. 5). Also, buspirone did not affect immobilityFig. 4. Effects of reboxetine on immobility in male and female wild-type (WT) and
transgenic mice (OE) in the FST. Data are presented as means þ SEM, *p < 0.05 vs.
vehicle (Veh).of female OE mice (p¼ 0.908; Fig. 5). Similar to male OE mice, 8 out
of 12 female OEmice showed abnormal swimming behaviour when
treated with 3.0 mg/kg buspirone. These animals were excluded
from the experiment (the remaining animals are shown as single
values in Fig. 5).
3.2.5. S 15535
S 15535 did not affect the immobility times of male WT
(p¼ 0.107), male OE (p¼ 0.925), femaleWT (p¼ 0.840) or female OE
(p ¼ 0.092) mice in the used doses (15, 30, 60 mg/kg).
4. Discussion
Prevalence of depression is twice as high inwomen than inmen,
but women were found to have better outcomes following anti-
depressant treatments (Yang et al., 2011). Despite this fact, several
studies suggest that SSRI are more effective and better tolerated in
women, so gender difference in antidepressant response still
remains a highly discussed topic (see Keers et al., 2010). On the one
hand depressive disorders are associated with alterations of the
5-HT1A-receptor and on the other hand gender differences in
5-HT1A-receptor binding have been demonstrated in men and
women (Jovanovic et al., 2008; Parsey et al., 2002). Hence, we
focused in this study on sex differences in 5-HT1A-receptor over-
expressing mice with regard to the 5-HT1A-receptor density and to
their response to antidepressants.
4.1. [3H]8eOHeDPAT binding
In a previous gross receptor autoradiography study with [3H]
8eOHeDPAT we revealed pronounced 5-HT1A-receptor over-
expression in the hippocampus and cortex of male transgenic mice
(Bert et al., 2006). In this study, we speciﬁed the brain regions,
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differences. In OE mice we observed most intense labelling (5e9-
fold) in three cortical sub-regions and in the CA3 region of the
hippocampus independently from sex. The surplus expression
occurs notably in the cortical layer III which contains a high number
of pyramidal cells, but is also found in layers I and II. The cortical
pattern of the over-expression in our transgenic mice resembles the
5-HT1A-receptor distribution in the cortex of humans, where the
receptor is also abundant in the outer cortical layers (Pazos et al.,
1987). We now observed that the surplus expression occurs also in
thewhole amygdala, as well as in the hypothalamus, lateral septum,
claustrum, and tenia tecta ofmale as well as female OEmice. Most of
these brain regions are thought to be part of the neuronal circuitry of
depression (Maletic et al., 2007). Again, as shown in our previous
study (Bert et al., 2006), 5-HT1A-receptor over-expression is not
apparent in the DRN or MRN of OE mice. Since there is no speciﬁc
5-HT1A-receptor antibody available for electron microscopy in mice
we were not able to determine the exact neuronal location of the
surplus receptors. However, Jolimay et al. (2000) have shown that
5-HT1A-receptors do not have the amino acid sequence which is
necessary to be transported into the axon of serotonergic neurons.
The genetic construct for generating our OE mice also does not
exhibit this sequence (Kusserow et al., 2004), which strongly
implicates that the surplus 5-HT1A-receptors are postsynaptically
expressed.
It could be argued that the over-expression is linked either to
altered afﬁnity or to abnormal coupling. In our earlier [3H]
8eOHeDPAT binding study we did not observe a difference in the
mean dissociation constant values Kd between WT and OE mice of
both genders (Bert et al., 2008). Non-physiological coupling does
not seem likely as we do see the expected pharmacological effects
after systemic administration of 8eOHeDPAT in the OE mice (Bert
et al., 2006, 2009). This assumption is supported by a study using
recombinant 5-HT1A-receptors showing that an increased recep-
tor:G-protein-ratio augments the potency and efﬁcacy of full and
partial agonists, respectively (Newman-Tancredi et al., 1997).
In the present studywe revealed for the ﬁrst time sex differences
in the 5-HT1A-receptor expression of OEmice. In female OEmicewe
detected signiﬁcantly higher [3H]8eOHeDPAT labelling in three
brain regions (parietal cortex, hypothalamus, and CA2 region of the
hippocampus) than in male OE mice. WT mice also displayed sex
differences in 5-HT1A-receptor binding: Female WT mice showed
higher 5-HT1A-receptor labelling compared tomaleWTmice (basal/
lateral amygdala, claustrum, and MRN). There is few data on sex
differences in mice available. Supporting our ﬁndings, in one study
which used NMRI mice, higher [3H]8eOHeDPAT binding was also
detected in female mice in distinct brain areas compared to male
NMRImice (Schiller et al., 2006). Sex differences in 5-HT1A-receptor
binding have been also described in humans with women showing
higher (up to 39%) 5-HT1A-receptor binding potential thanmen (e.g.
Jovanovic et al., 2008; Parsey et al., 2002; Stein et al., 2008).
4.2. Forced swim behaviour and effects of antidepressants
4.2.1. Male animals
The over-expression of postsynaptic 5-HT1A-receptors in male
transgenic mice is associated with an antidepressant-like pheno-
type in the FST, as indicated by lower immobility compared to male
WT mice. This phenotype is not due to a generally higher motor
activity of male OE mice as we have previously observed that male
OE mice were even less active than male WT mice in an open ﬁeld
arena (Bert et al., 2006). The antidepressant-like behaviour of male
OEmicewas conﬁrmed by a hedonic response in amodiﬁed version
of the sucrose preference-test, where male OE mice favoured a 2%
sucrose solution over water (own observation). We suggest that theantidepressant-like phenotype can be attributed to the robust
5-HT1A-receptors over-expression in the cortex and in the CA3
region. Complementary to our transgenic mice Richardson-Jones
et al. (2009) generated mutant mice with a developmental
suppression of postsynaptic 5-HT1A-receptors. This suppression
leads to increased depression-related behaviour in transgenic mice,
which supports our ﬁnding that postsynaptic 5-HT1A-receptors are
involved in the pathophysiology of depression.
It has to be noted that the antidepressant-like phenotype of
male OE mice was absent in the vehicle-treated group. We suggest
that the injection procedure itself was a stressful event, which
affected the depression-related behaviour in the FST. In several
studies the injection procedure of saline has been shown to be
a stressor and to elicit an anxiogenic effect (Lapin, 1995; Ryabinin
et al., 1999). Similar to our observation, Leggio et al. (2008)
described that vehicle treatment can differently affect the behav-
iour of wild-type andmutantmice in the FST. In their study vehicle-
treated D3-receptor knockout mice showed no increase in immo-
bility indicating a higher stress resistance in contrast to wild-type
mice, which displayed higher immobility after vehicle treatment
(Leggio et al., 2008). In the case of our transgenic mice, male OE
mice seemed to be more vulnerable to stress caused by the injec-
tion procedure, which could be explained by an increased activa-
tion of the long negative feedback mechanism mediated by
postsynaptic 5-HT1A-receptors (Hajos et al., 1999). Forced swim-
ming and vehicle injectionwere both found to increase 5-HToutput
in the raphe nuclei and forebrain structures (Adell et al., 1997).
Hence, it is possible that in our male OE mice the increased 5-HT-
release induced by the ﬁrst stressor (saline injection) ampliﬁed the
long negative feedback mechanism due to the higher number of
postsynaptic receptors. As the second stressor (forced swimming)
was submitted, a further increase of 5-HT release could not be
achieved which has resulted in a depressant-like response of male
OE mice.
The FST is considered to be a valid model for studying antide-
pressant drug effects following acute as well as chronic adminis-
tration in rats and mice. Reduced immobility time has been
interpreted as behavioural despair and points towards a potentially
antidepressant drug effect (Cryan and Mombereau, 2004; Porsolt
et al., 1978). SSRIs like citalopram have been shown to decrease
immobility time after acute treatment in mice (David et al., 2003;
Sanchez and Meier, 1997). It is conceivable that motor stimulant
effects may contribute to the antidepressant-like effect of cit-
alopram in the FST, as both drug effects may overlap. In male WT
mice citalopram reduced immobility in the FST, but both effective
doses were also shown to induce hyperactivity in the OFT. Only in
male OE mice a clear-cut antidepressant effect of citalopram
without any interference with motor activity was observed, sug-
gesting a pronounced effect of citalopram in transgenic mice. This
enhanced response of transgenic mice argues for an involvement of
postsynaptic 5-HT1A-receptors in the efﬁcacy of citalopram.
Several studies show that citalopram induces hyperlocomotion
in mice (Crowley et al., 2005; David et al., 2003). By employing
various antagonists at different 5-HT-receptors Millan et al. (2003)
were able to relate citalopram induced hyperactivity to the acti-
vation of 5-HT1B- and 5-HT2A-receptors, but not of 5-HT1A-recep-
tors. However, they used the 5-HT1A-antagonist WAY-100635
which binds to both, 5-HT1A-auto- and -heteroreceptors. Since in
our study the 5-HT1A-receptor over-expression in corticolimbic
areas counteracted the motor stimulant effects of citalopram in the
OFT and since citalopram produced distorted swimming behaviour
in some OE mice in the FST we suggest that postsynaptic 5-HT1A-
receptors are also involved in the locomotor effects of citalopram.
Reboxetine is a potent and selective NARI with weak additional
binding properties (Wong et al., 2000). It was shown that reboxetine
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FST (Millan et al., 2001; Nielsen et al., 2004). Due to itsmechanism of
actionwe expected a similar response to reboxetine in maleWTand
male OE mice. However, in our study reboxetine did not affect
immobility ofmaleWTandmale OEmice in the FST. Our observation
is supported by the ﬁnding of Andreasen et al. (2009a; 2009b)which
repeatedly showed that high doses (20 and 30 mg/kg) of reboxetine
did not alter swimming behaviour of mice in the FST. Other studies
observed that the antidepressant effect of reboxetine appeared only
when administered in high doses (Cryan et al., 2005a; Millan et al.,
2001; Nielsen et al., 2004;Wonget al., 2000). Althoughwe increased
the dose up to 40mg/kg, reboxetine failed to decrease immobility in
male mice of both genotypes. However, the response to reboxetine
seems to dependon thegenderas in our study reboxetine induced an
antidepressant-like response in female WT mice.
The desensitisation of presynaptic 5-HT1A-receptors seems to be
a key mechanism in the pharmacotherapy of depression when
5-HT1A-receptor agonists are combined with SSRIs (see reviews by
Blier and Ward (2003) and Celada et al. (2004)). It has also been
discussed that direct activation of postsynaptic 5-HT1A-receptors
ameliorates antidepressant therapy (see Savitz et al. (2009) for
review). In clinical practice only partial 5-HT1A-receptor agonists like
gepirone, ipsapirone, and buspirone, which possess only weak
antidepressant properties, are used (McGrath et al., 1994; Robinson
et al., 1990; Stahl et al., 1998). One reason for the attenuated clinical
efﬁcacy of partial 5-HT1A-receptor agonists could be that they exert
only a weak agonistic effect at postsynaptic 5-HT1A-receptor sites
because of the lack of receptor reserve in serotonergic projection
areas. We expected that OE mice would show a more pronounced
response to the partial agonist buspirone compared toWTmice. This
is based on our assumption that surplus 5-HT1A-receptors lead to an
artiﬁcial postsynaptic receptor reserve where partial agonists would
exhibit full agonist effects. However, buspirone increased immobility
in male WT mice accompanied by decreased ambulatory activity in
the OFT. The “depression-like” response to buspirone in the FST
might bya result of a general hypomotor effect. InmostmaleOEmice
the same dose of buspirone caused abnormal swimming behaviour.
It is conceivable that these severe alterations of motor function
surmounted a potential antidepressant-like activity of buspirone in
the FST.We conclude that thesemotor disturbances aremediated by
postsynaptic 5-HT1A-receptors. This is supported by our previous
ﬁnding that the full 5-HT1A-receptor agonist 8eOHeDPAT provoked
an exaggerated response in OE mice, apparent as decreased loco-
motor activity in the OFT and as a pronounced serotonin-syndrome
already at low doses (Bert et al., 2006).
In comparison to buspirone the partial 5-HT1A-receptor agonist
S 15535 has a lower intrinsic activity (about 25e30% vs. 62% for
buspirone) and shows higher 5-HT1A-receptor occupancy at post-
synaptic than at presynaptic sites (Newman-Tancredi et al., 1998a,
1998b). Hence, S 15535 is thought to be a functional antagonist at
postsynaptic sites, whereas it acts rather like an agonist at presyn-
aptic sites due to thehigh receptor reserve in the raphenuclei (Millan
et al., 1994). In our experiments, S 15535 failed to alter immobility
time of male WT and OE mice in the FST. This result matches the
ﬁndings from two other studies where the acute administration of S
15535 did not affect immobility time of either rats (Millan et al.,
1997) ormice (Bourin et al.,1998).Wedidnot observe an inﬂuence of
S 15535 onmotor functions of transgenic mice as we have seen after
buspirone or 8eOHeDPAT (Bert et al., 2006). We assume that
S 15535 is barely able to stimulate the over-expressed postsynaptic
5-HT1A-receptor sites due to its low intrinsic activity.
4.2.2. Female mice
In contrast to male OE mice we observed no antidepressant-like
phenotype in untreated female OEmice. Thiswas surprising as femalemice showa similar degree of 5-HT1A-receptor over-expression and in
three brain regions (parietal cortex, CA2, and hypothalamus) even to
higher extent than male OE mice. A reason for the absence of an
antidepressant-like phenotype in female OE mice could be the sex
difference in 5-HT1A-receptor expression in the parietal cortex, CA2,
and hypothalamus of OE mice. In these regions 5-HT1A-receptors co-
exist with oestrogen receptors (Weiser et al., 2008) and it is possible
that these two receptor types closely interact.
Only in female OEmice, but not in femaleWTmice, both doses of
citalopram reduced immobility time similar to males indicating
a clear-cut antidepressant effect without affecting locomotor activity
in the OFT. However, some female OE mice also showed distorted
swimming behaviour. This strengthens our observations in male OE
mice and conﬁrms that the corticolimbic over-expression of 5-HT1A-
receptors contributes on the one hand to the antidepressant and on
the other hand to the motor effect of citalopram.
In contrast to male WT mice, the dose of 20 mg/kg reboxetine
was sufﬁcient to produce an antidepressant-like effect in female
WT mice. This effect appeared despite the hypolocomotor effect in
the OFT. To our knowledge there is no report in literature on sex
differences of reboxetine effects in laboratory rodents. The sex
differences in the effects of reboxetine in our study are supported
by clinical ﬁndings of Khan et al. (2005) who reported a trend for
a higher responsiveness towards NARIs in depressed women
compared to depressed men.
Similar to males, the partial 5-HT1A-receptor agonist buspirone
had no antidepressant effect in female WT and OE mice. We also
observed abnormal swimming behaviour after the administration
of the highest dose of buspirone in female OE mice as described for
male OE mice. S 15535 also did not evoke an antidepressant
response in female WT and OE mice, which coincides with our
ﬁndings gained in male WT and OE mice.
Summarising, our data suggest that the postsynaptic 5-HT1A-
receptor is still a promising target for the therapy of depression. This is
highlighted by the development of the highly selective postsynaptic
5-HT1A-receptor agonist F15599 that yields a good antidepressant-like
proﬁle in rats (Assie et al., 2010). The results also indicate that the
observedaberrantmotor effects aremediatedbypostsynaptic 5-HT1A-
receptors and may contribute to unwanted side effects.
5. Conclusion
The detailed quantitative receptor autoradiography study with
[3H]8eOHeDPAT revealed a pronounced 5-HT1A-receptor over-
expression in various corticolimbic areas in male and female
transgenic mice. Sex differences in the expression pattern were
seen in both genotypes with females displaying generally a higher
5-HT1A-receptor density than male mice. The selective over-
expression of postsynaptic 5-HT1A-receptors is associated with
a clear-cut antidepressant response to the SSRI citalopram, but not
to the NARI reboxetine. However, for all drug treatments sex
differences were relevant for the outcome of the antidepressant-
like drug effects. Though further pharmacological analysis is
required, these data provide novel support for the role of post-
synaptic 5-HT1A-receptors in the antidepressant actions of SSRIs
and unwanted motor side effects.
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